logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Life Science
Filter

Life Science

Categories

Sectors

Locations

Exchange

美股基因组股票投资指南:押注木头姐的“基因组革命”

Insiders Sell Nearly $900,000 in Stock as Monterosa Medical Faces Key Clinical Data Test

Jun 29, 2026

Life Science

医药保险巨头CVS Health股价飙升的原因是什么?

CVS Health Launches One-Stop Service Plan for GLP-1 Weight Loss Drugs

Jun 26, 2026

Life Science

Kymera Jumps on Rapid Eczema Trial Enrollment; Takeover Talk Swirls

Kymera Jumps on Rapid Eczema Trial Enrollment; Takeover Talk Swirls

Jun 26, 2026

Life Science

这家制药公司因大流行成为焦点,如果5年前向它投资会怎样?

Innovative Pipeline Supports Long-Term Value, Moderna Still Has Upside After Doubling in Price

Jun 26, 2026

Life Science

Merck KGaA’s $11.3 Billion Bio-Techne Buy Bolsters CGT Ambitions in Biggest Deal Since 2014

Merck KGaA’s $11.3 Billion Bio-Techne Buy Bolsters CGT Ambitions in Biggest Deal Since 2014

Jun 25, 2026

Life Science

分析师看好+临床数据强劲,Relay Therapeutics股价周涨近15%

Impressive Clinical Trial Data Drives Intellia Therapeutics Up 70% This Year

Jun 25, 2026

Life Science

Seeking Reliable Income? Top Picks in High-Yield Healthcare Stocks

How Should Investors Weigh the Trade-Off Between Amgen and Iovance?

Jun 24, 2026

Life Science

2x Valuation Gap: BIO vs. CRL — Who’s Wrong?

2x Valuation Gap: BIO vs. CRL — Who’s Wrong?

Jun 23, 2026

Life Science

生物科技投资可能面临高风险,ProKidney股价暴涨600%

Mid-Cap Biotech Viking Therapeutics Could Emerge as a Potential Challenger to Eli Lilly and Novo Nordisk

Jun 23, 2026

Life Science

Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee

Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee

Jun 22, 2026

Life Science

Why CRISPR Therapeutics Stock Is Stuck Despite Boasting the World’s First Approved CRISPR Therapy

Why CRISPR Therapeutics Stock Is Stuck Despite Boasting the World’s First Approved CRISPR Therapy

Jun 18, 2026

Life Science

Hims & Hers宣布收购实验室设施,股价随之飙升

CVS Health Shows Strong Recovery Momentum, Valuation Remains Attractive

Jun 16, 2026

Life Science

高股息医疗股怎么选?强生与美敦力的优势与挑战

Healthcare Expenditures Continue to Grow, Three Leading Stocks Lead the 2026 Investment Race

Jun 16, 2026

Life Science

寻找科技股以外的增长极,Vertex Pharmaceuticals正当其时

Is It Time to Buy This Turnaround Pharma Stock?

Jun 12, 2026

Life Science

Parabilis Shatters Biotech IPO Record, Stock Surges 58% in Nasdaq Debut

Parabilis Shatters Biotech IPO Record, Stock Surges 58% in Nasdaq Debut

Jun 12, 2026

Life Science

Tempus AI Stock Lifted by Analyst Optimism and Subsidiary's Tech Breakthrough

The Stock Price of UnitedHealth Group Still Falls More Than 30% from Two Years Ago, and Policy Dependency Becomes a Key Investment Consideration 

Jun 12, 2026

Life Science

RVMD Skyrockets 285% in a Year on Historic Pancreatic Cancer Drug Breakthrough

RVMD Skyrockets 285% in a Year on Historic Pancreatic Cancer Drug Breakthrough

Jun 11, 2026

Life Science

FDA宣布了一个消息,这家生物技术公司股价飙升约20%

The iShares U.S. Pharmaceutical ETF Has Achieved a Return of Over 42% in the Past Year

Jun 11, 2026

Life Science

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada